Currently, there are 273.81M common shares owned by the public and among those 241.81M shares have been available to trade.
The company’s stock has a 5-day price change of -3.45% and 5.95% over the past three months. PACB shares are trading -80.02% year to date (YTD), with the 12-month market performance down to -77.88% lower. It has a 12-month low price of $1.16 and touched a high of $10.65 over the same period. PACB has an average intraday trading volume of 9.70 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.86%, -0.97%, and -6.08% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Pacific Biosciences of California Inc (NASDAQ: PACB) shares accounts for 83.15% of the company’s 273.81M shares outstanding.
It has a market capitalization of $514.46M and a beta (3y monthly) value of 1.95. The earnings-per-share (ttm) stands at -$1.46. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.19% over the week and 10.77% over the month.
Earnings per share for the fiscal year are expected to decrease by -12.49%, and 49.56% over the next financial year. EPS should grow at an annualized rate of -1.00% over the next five years, compared to -9.76% over the past 5-year period.
Jefferies coverage for the Pacific Biosciences of California Inc (PACB) stock in a research note released on June 03, 2024 offered a Buy rating with a price target of $4. JP Morgan was of a view on April 22, 2024 that the stock is Neutral, while Goldman gave the stock Neutral rating on April 18, 2024, issuing a price target of $7- $2.50. Stephens on their part issued Overweight rating on December 14, 2023.
